Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen

Mundipharma opens its doors to local schools to inspire the next generation of scientists

Mundipharma wins 1st ever PLG deal of the year award for acquisition of Cinfa Biotech

Mundipharma appoints Patrice Grand as European Director of Corporate Communications

Mundipharma launches Pelmeg®▼(pegfilgrastim) biosimilar in Europe

Mundipharma announces Marco Cerato as Senior Vice President Business Development and Strategic Partnerships

flutiform® receives a positive opinion in Europe for the Treatment of Children with Asthma

New guidance from ADA and EASD recommends use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for patients with type 2 diabetes

Mundipharma strengthens position as a leader in biosimilars with acquisition of development company Cinfa Biotech

Mundipharma announces Philippe Bastide as Head of Biosimilars